By 2023, patents on nearly 20 oncology biologics will expire, which could lead to more biosimilars in cancer care and therefore reduced costs, according to a review article.
Biologics currently make up half of the pharmacological market for oncology, but the steep cost of these drugs is a barrier to access. By 2023, patents on nearly 20 oncology biologics will expire, which could lead to more biosimilars in cancer care and therefore reduced costs, according to a review article.
Data supporting the effectiveness and safety of biosimilars has accumulated since 2003, when the European Medicines Agency (EMA) launched its biosimilar regulatory and approval process. The FDA began regulating biosimilars in 2009. Both EMA and FDA approve biosimilars demonstrated to have no clinically meaningful differences in purity, safety, and efficacy compared to their respective reference products.
Nonetheless, biosimilars are not identical to their reference products, which has slowed acceptance by physicians and patients. The authors cite previous research suggesting a lack of understanding of and familiarity with biosimilars among oncologists. The authors also note no biosimilar has been approved by the FDA as interchangeable with its reference biologic.
Immunogenicity is a major concern of physicians familiar with biosimilars. The authors acknowledge small changes in the structure of the biologic or a different route of administration could increase the risk of adverse events. They stress the importance of pharmacovigilance and collection of long-term safety data of approved biosimilars to improve physician confidence in biosimilars.
The authors discuss the biologics for which biosimilars are currently approved as treatment or supportive care of cancer in Europe and/or the United States. As of the date the article first published last fall, the authors said:
The authors stress the need to educate physicians and patients about the safety and efficacy of biosimilars and collect long-term safety data to improve their acceptance and promote their use in routine cancer treatment.
Reference
Konstantinidou S, Papaspiliou A, Kokkotou E. Current and future roles of biosimilars in oncology practice. Oncol Lett. 2020;19(1):45—51. doi:10.3892/ol.2019.11105.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
2 Commerce Drive
Cranbury, NJ 08512